Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 8, 2013

Primary Completion Date

August 26, 2025

Study Completion Date

August 26, 2025

Conditions
Ovarian CancerFallopian Tubes CancerPeritoneal Cancer
Interventions
PROCEDURE

Secondary Cytoreductive Surgery

DRUG

Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

DRUG

platinum-based systemic chemotherapy postoperatively

5 cycles

DRUG

platinum-based systemic chemotherapy postoperatively

6 cycles

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau (All protocol activities, except surgery), Uniondale

11725

Memorial Sloan Kettering Commack, Commack

33143

Baptist Health South Florida, Miami

55905

Mayo Clinic, Rochester

60637

University of Chicago Medical Center, Chicago

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford

Unknown

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

Baptist Health South Florida

OTHER

collaborator

Hartford HealthCare

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Chicago

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01767675 - Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter